Zacks Research Has Optimistic Outlook of PBH FY2025 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at Zacks Research lifted their FY2025 earnings estimates for Prestige Consumer Healthcare in a report released on Tuesday, January 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.51 for the year, up from their previous estimate of $4.43. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q1 2026 earnings at $1.02 EPS, Q4 2026 earnings at $1.30 EPS, Q1 2027 earnings at $1.12 EPS, Q2 2027 earnings at $1.24 EPS and FY2027 earnings at $4.98 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the previous year, the company earned $1.07 EPS. The business’s quarterly revenue was down .9% compared to the same quarter last year.

PBH has been the topic of a number of other research reports. DA Davidson reissued a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday, January 7th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $77.14 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. Prestige Consumer Healthcare has a 1-year low of $58.22 and a 1-year high of $86.36. The firm has a market capitalization of $3.81 billion, a P/E ratio of 18.77, a P/E/G ratio of 2.08 and a beta of 0.51. The business’s 50-day simple moving average is $80.59 and its 200-day simple moving average is $74.39.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in PBH. Quest Partners LLC grew its stake in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC increased its holdings in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank lifted its position in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. This represents a 33.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.